Eckert & Ziegler Strahlen- und Medizintechnik Bundle
Who owns Eckert & Ziegler Strahlen- und Medizintechnik AG?
Founded in 1992 by Dr. Andreas Eckert and Dr. Joachim Ziegler, the Berlin-based isotope specialist moved from founder-led control to broad institutional and retail ownership after pandemic-era demand. Its shares trade on Xetra (EUZ) under Prime Standard, with a notable free float and ongoing founder/insider stakes.
Major shareholders in 2024/2025 are European institutional funds and retail investors, while founders retain significant voting influence; governance shifts reflect theranostics-driven growth and expanding institutional participation. See Eckert & Ziegler Strahlen- und Medizintechnik Porter's Five Forces Analysis
Who Founded Eckert & Ziegler Strahlen- und Medizintechnik?
Founders and Early Ownership of Eckert & Ziegler Strahlen- und Medizintechnik trace to nuclear physicists Dr. Andreas Eckert and Dr. Joachim Ziegler, who established the firm in the early 1990s with founders and a small employee circle owning virtually all equity; Eckert emerged as the controlling founder while Ziegler led technical strategy.
Founding roles
Dr. Andreas Eckert acted as entrepreneurial lead; Dr. Joachim Ziegler led scientific and technical development for brachytherapy and isotopes.
Early capitalization
Initial funding relied on reinvested cash flow and modest bank loans; there is no record of classic venture capital rounds.
Equity distribution
By the late 1990s Eckert held a clear majority, Ziegler a meaningful minority, and managers held small option pools vesting over 3–4 years.
Governance clauses
Founders adopted buy-sell and good-leaver/bad-leaver provisions typical of German Mittelstand firms preparing for listing.
Pre-IPO restructuring
Share consolidations and internal transfers increased Eckert’s control to support strategic acquisitions while Ziegler retained technical influence.
Dispute record
No major early ownership disputes were reported publicly; restructurings focused on integrating isotope assets and managing regulatory liabilities.
Early ownership arrangements shaped long-term Eckert & Ziegler ownership, with founders' stakes, manager option pools, and later institutional investor entries documented in annual reports and shareholder registries; see the Brief History of Eckert & Ziegler Strahlen- und Medizintechnik for more context.
Key facts
Founders, ownership dynamics, and governance mechanisms that influenced early corporate strategy and the IPO process.
- Founders: Dr. Andreas Eckert (controlling), Dr. Joachim Ziegler (technical).
- Capital: internal cash flow and bank finance; limited friends-and-family participation.
- Options: manager pools vesting over 3–4 years tied to brachytherapy and isotope milestones.
- Pre-IPO: share consolidations increased Eckert’s control; Ziegler retained technical influence.
Eckert & Ziegler Strahlen- und Medizintechnik SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Eckert & Ziegler Strahlen- und Medizintechnik’s Ownership Changed Over Time?
Key events shaping Eckert & Ziegler ownership include the 1999–2000 IPO on Neuer Markt, progressive dilution through 2000s–2010s acquisitions and employee programs, a theranostics-driven market cap surge to over €1 bn in 2018–2021, and 2022–2024 normalization with sustained institutional ownership and strategic investments in isotope capacity.
| Period | Ownership Dynamics | Impact on Stakeholders |
|---|---|---|
| 1999–2000 | IPO on Neuer Markt/Prime Standard; founders retained effective control; initial market cap in the low hundreds of millions € | Founders remained largest identifiable insiders; public float established |
| 2000s–2010s | Growth financed by new shares, acquisitions, employee participation; index inclusions (SDAX/other small-cap indices) increased passive holdings | Founder stakes diluted to high single-digit/low teens %; passive/institutional holdings rose |
| 2018–2021 | Theranostics demand (Lu-177, Ga-68, I-125) lifted revenues and share price; market cap peaked > €1 bn | Inflow of European institutions and healthcare investors; free float and liquidity expanded |
| 2022–2024 | Valuation compression from rising rates; steady institutional ownership; continued capex in radiopharma supply and isotopes | Governance shifted toward greater board independence; capital allocation focused on regulated capacity and long-term contracts |
Current ownership (2024/2025) reflects a mix of founder insider holdings, diversified institutional investors, and passive fund exposure; Germany’s ≥3% disclosure threshold frames publicly reported major shareholders.
Major stakeholders and trends
Ownership today balances founder continuity with broad institutional and passive investor presence, supporting strategic investments in isotope supply and selective M&A.
- Dr. Andreas Eckert and related holdings: single largest identifiable insider, typically disclosed above 3%, historically in the high single-digit to low-teens % range
- Collective free float/institutional holders: largest block, including European asset managers, German insurers/pension funds, and SDAX-linked passive funds
- Other insiders/management: smaller direct and long-term incentive holdings; board independence has increased
- No disclosed controlling government or corporate parent stake; company operates independently
For registry detail, filings and annual reports show periodic 3%+ disclosures and institutional position changes; see further company market context in the Target Market of Eckert & Ziegler Strahlen- und Medizintechnik
Eckert & Ziegler Strahlen- und Medizintechnik PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Eckert & Ziegler Strahlen- und Medizintechnik’s Board?
The current Board of Directors of Eckert & Ziegler Strahlen- und Medizintechnik AG follows the German two-tier system: a Supervisory Board overseeing strategy and an Executive Board running operations, with founder-linked representation alongside independent industry and finance professionals.
| Name | Role | Focus / Notes |
|---|---|---|
| Dr. Andreas Eckert (or allied member) | Founding family representative (Historically on Aufsichtsrat) | Founder/insider influence; may reflect family ownership interests |
| Supervisory Board members (independent) | Supervisory Board | Industry, finance and audit oversight; responsible for appointing Executive Board |
| Executive Board members | Management (Vorstand) | Operational heads for Radiopharma, Medical/Isotopes, and Finance |
Voting follows one-share-one-vote; no public dual-class or golden shares are disclosed, so control is proportional to shareholdings and influenced by institutional investors, proxy advisors and founder/insider stakes.
Board composition and voting dynamics
Supervisory Board oversight, Executive Board execution, and proportional voting shape governance at Eckert & Ziegler.
- Voting structure: one-share-one-vote; no dual-class shares disclosed
- Insider/founder presence stabilizes outcomes despite institutional free float
- AGM topics: remuneration, audit oversight, sustainability attract institutional voting
- No widely publicized proxy battles resulting in board turnover through 2024–2025
Institutional investors often constitute the majority of the free float; latest filings show top institutional holders commonly in the single-digit to low double-digit percentage range each, with aggregate institutional ownership typically above 50%, affecting Eckert & Ziegler ownership outcomes and shareholder registry disclosures — see the company’s annual report and this analysis: Growth Strategy of Eckert & Ziegler Strahlen- und Medizintechnik
Eckert & Ziegler Strahlen- und Medizintechnik Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Eckert & Ziegler Strahlen- und Medizintechnik’s Ownership Landscape?
Recent shifts in Eckert & Ziegler ownership reflect rising institutional and passive investor participation since 2021, concentrating voting power among global asset managers while founders remain meaningful shareholders; share count changes through 2024 stemmed mainly from employee programs and targeted financings tied to capacity expansion.
| Trend | Impact |
|---|---|
| Institutionalization (2021–2024) | Inclusion in European small-cap indices and sector ETFs raised passive ownership to an estimated 25–35% of free float, stabilizing the register but concentrating votes with large asset managers and proxy advisors. |
| Capital measures | Preference for organic investment and selective capacity projects; no large dilutive raises or transformational buybacks announced through 2024; share count moves mainly from employee programs and small financings. |
| Strategic investments | Expansion in radiopharma supply (Lu-177 precursor capacity, generator logistics) and contract manufacturing improved revenue visibility, attracting long-only institutions and supporting gradual free-float growth. |
| Insider and founder stakes | Founder holdings diluted over time due to index-driven inflows but remain material; founders retain soft influence via reputation and sector networks rather than majority control. |
| Industry governance trends | Higher institutional and passive ownership increased demands for governance transparency, ESG disclosure and capital discipline; no activist campaign against the company disclosed as of 2025. |
| Outlook | Future ownership shifts likely from incremental institutional accumulation, potential strategic radiopharma partnerships, or modest equity issuance for bolt-on acquisitions or capacity expansion; management signals continued independence and succession planning under Germany’s Corporate Governance Code. |
Institutional ownership concentration influences voting dynamics and governance priorities, while strategic investments in radiopharma supply strengthen appeal to long-term investors and support steady free-float evolution.
Indexed ownership growth
Index and ETF inclusion from 2021–2024 lifted passive holdings to roughly 25–35% of free float, concentrating voting influence among a few global managers.
Capital discipline
No transformational buybacks through 2024; capital allocated to organic growth and selective capacity projects, with small financing rounds and employee share programs accounting for share count changes.
Founder influence
Founders diluted over time but remain material shareholders and maintain sector influence via networks and reputation rather than outright control.
Where to read more
For deeper context on peers and market positioning see Competitors Landscape of Eckert & Ziegler Strahlen- und Medizintechnik.
Eckert & Ziegler Strahlen- und Medizintechnik Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What is Competitive Landscape of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What is Growth Strategy and Future Prospects of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- How Does Eckert & Ziegler Strahlen- und Medizintechnik Company Work?
- What is Sales and Marketing Strategy of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What are Mission Vision & Core Values of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What is Customer Demographics and Target Market of Eckert & Ziegler Strahlen- und Medizintechnik Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.